ARCHIVES

Hearing Scheduled To Investigate ImClone’s C225 Development, Stock Trading

This article is from The Cancer Letter archive.

Vol. 28 No. 23 | June 7, 2002

Download PDF Visit The Full Archive

Related Articles

NCAB To Hear Program Reviews, Try Again On Act Revisions

October 22, 1976

FDA Accepts DCT Board’s Criteria For Approval Of New Drugs, Explains Plan for Early Action

February 17, 1989

Groups Advise NCI On “Investment Opportunities”

June 28, 1996

Charles Moertel, Mayo Clinic Investigator, Advocate Of Rigorous Trials, Dead At 66

July 8, 1994

NAS Honors David Kessler; Satcher Seeks Obesity Plan.

January 12, 2001

DCCP Board Approves Concept Of NMR Interintuitional Clinical Research

January 27, 1984